Brief: Ose Immunotherapeutics Updates On Anti-IL-7 Receptor Antagonist OSE-127/S95011

Ose Immunotherapeutics SA

22/02/2023 17:47

Feb 22 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * UPDATES ON ANTI-IL-7 RECEPTOR ANTAGONIST OSE-127/S95011, A
BREAKTHROUGH APPROACH IN CHRONIC INFLAMMATORY AUTOIMMUNE
DISEASES AND HEMATOLOGY
    * POSITIVE PHASE 1 CLINICAL RESULTS PUBLISHED IN ' JOURNAL
OF
IMMUNOLOGY'
    * TWO ONGOING PHASE 2 CLINICAL TRIALS IN ULCERATIVE COLITIS
AND
PRIMARY SJÖGREN'S SYNDROME
    * POSITIVE PRECLINICAL EFFICACY DATA IN ACUTE LYMPHOBLASTIC
LEUKEMIA

Source text for Eikon:  ID:nBw7z3QTVa 
Further company coverage:  OSE.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))